GRCL
Gracell Biotechnologies Inc

654
Loading...
Loading...
News
all
press releases
Gracell Biotechnologies (NASDAQ:GRCL) Earns "Hold" Rating from Stifel Nicolaus
Stifel Nicolaus restated their hold rating on shares of Gracell Biotechnologies (NASDAQ:GRCL Free Report) in a report released on Thursday morning, Benzinga reports. Stifel Nicolaus currently...
Ticker Report·2y ago
News Placeholder
More News
News Placeholder
Gracell Biotechnologies Acquisition Completed
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ( Gracell or the Company , Nasdaq: GRCL), a global clinical-stage biopharmaceutical...
Globe Newswire·2y ago
News Placeholder
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR...
SeekingAlpha·2y ago
News Placeholder
Gracell Biotechnologies Sees Unusually High Options Volume (NASDAQ:GRCL)
Gracell Biotechnologies Inc. (NASDAQ:GRCL Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders purchased 13,143 put options on the company. This is an...
Zolmax·2y ago
News Placeholder
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ( Gracell or the Company , NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Globe Newswire·2y ago
News Placeholder
Gracell Biotechnologies (NASDAQ:GRCL) Sets New 12-Month High at $10.36
Shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL Get Free Report) hit a new 52-week high during trading on Friday . The company traded as high as $10.36 and last traded at $10.36, with a...
Zolmax·2y ago
News Placeholder
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myelomaSAN DIEGO and SUZHOU...
Globe Newswire·2y ago
News Placeholder
ALERT: The M&A Class Action Firm Continues Investigating the Merger GRCL, AXNX, HARP, CVLY
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm ), a national securities...
Globe Newswire·2y ago
News Placeholder
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates PGTI, KRTX, THRX, GRCL
NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
Globe Newswire·2y ago
News Placeholder
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL PR Newswire NEW YORK...
PR Newswire·2y ago

Latest GRCL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.